EMEA-002489-PIP01-18 - paediatric investigation plan

rivoceranib (mesilate)

Key facts

• Active substance:
  rivoceranib (mesilate)
• Therapeutic area:
  Oncology
• Decision number:
  P/0140/2019
• PIP number:
  EMEA-002489-PIP01-18
• Pharmaceutical form(s):
  Film-coated tablet
• Route(s) of administration:
  Oral use
• Decision type:
  W: decision granting a waiver in all age groups for all conditions or indications
• Decision date:
  17/04/2019
• Compliance check done:
  No

Decision

P/0140/2019: EMA decision of 17 April 2019 on the granting of a product specific waiver for rivoceranib (mesylate) (EMEA-002489-PIP01-18)

Adopted Reference Number: EMA/190164/2019